Release Date: Mar 2018
CC: PC, MK, PBL
Xinjie Xu, PhD, FACMG
Medical Director, ARUP Laboratories, Salt Lake City, UT; Assistant Professor, University of Utah School of Medicine, Salt Lake City, UT
Genomic profiling including detecting SNVs/indels, CNVs, CN-LOH, and translocation/fusion is critical in the diagnosis, prognosis, and treatment selection for patients with hematological malignancies. Currently, multiple testing strategies, including karyotype analysis, FISH, genomic microarray, and a variety of molecular testing methods, are being used for comprehensive genomic profiling in these patients. However, it is expensive and labor-intensive to perform multiple tests on patients. In addition, the correlation between different genetic tests is challenging.
In this webcast, Dr. Xinjie Xu will present the current progress and challenges of using next generation sequencing (NGS) for detecting different types of genetic abnormalities. With rapidly evolving technology and informatics, NGS has great potential in the future to be applied in routine clinical testing for comprehensive genomic profiling of patients with hematological malignancies.
After attending this session, participants will be able to:
- Recognize the significance of genomic profiling in patients with hematologic malignancies.
- Identify the limitations of conventional genetic testing in patients with hematologic malignancies.
- Explain the principle and challenge of detecting structural variations including copy number variations (CNVs), copy neutral loss of heterozygosity (CN-LOH), and translocation/fusion by next generation sequencing (NGS).
- Describe the advantage of comprehensive genomic profiling for patients with hematological malignancies using next generation sequencing (NGS).
Who should attend? Practicing Pathologists, Residents, Doctoral Scientists, Pathologists’ Assistants, Laboratory Managers, Bench Supervisors, Bench Technologists and Technicians, Cytotechnologists, Histotechnologists, Phlebotomists, Students